Cyclosporine In Takotsubo Syndrome

Prior treatment

• Infection (defined as concomitant infection with a positive blood culture at the time of study inclusion)
• Current medication with any compound containing Hypericum perforatum (St. John's worth) or Stiripentol or Aliskiren or Bosentan or Rosuvastatine (Rosuvastatine \>5mg within 24h intake\<48h before IMP administration)
• Any disorder associated with immunological dysfunction ≤6 months prior to presentation (autoimmune disease, known positive serology for HIV or hepatitis)
• Immunosuppressive, chemotherapeutical, or antibody treatment

Other illness

• Acute coronary syndrome (ACS) with significant coronary stenosis potentially associated with wall motion abnormalities (WMA) or percutaneous coronary intervention (PCI)
• History of hypersensitivity to cyclosporine
• History of hypersensitivity to egg, peanut or soybean proteins
• History of liver insufficiency
• Uncontrolled hypertension at the time of screening for study inclusion (systolic blood pressure \>180mmHg and/or diastolic blood pressure \>110mmHg)

Lab values

• History of chronic renal insufficiency (either creatinin clearance \<30 ml/min/1.73m² or current medical care for severe renal insufficiency)

Age

• Female patients currently pregnant or women of childbearing age without negative pregnancy test or without effective contraception

Other

• Participation in other clinical trials except for non interventional trials

• Patients aged over 18
• Enrollment and first IMP administration within 24 hours after cardiac catheterization
• Regional Wall Motion Abnormality (WMA) consistent with TTS in angiography or echocardiography
• InterTAK prognostic score- or a GEIST Score ≥ 9 -
• Written informed consent